Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04531670 · ClinicalTrials.gov registry record · NA
Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program
A NA study of Opioid Use Disorder and HIV Prevention Program, sponsored by University of Connecticut.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04531670: Completed NA study of Opioid Use Disorder and HIV Prevention Program, sponsored by University of Connecticut.
NCT04531670 is a NA study of Opioid Use Disorder and HIV Prevention Program that has completed, run by University of Connecticut. The registered enrollment target is 50 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04531670, a NA study of Opioid Use Disorder and HIV Prevention Program, has completed, sponsored by University of Connecticut.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).
Primary Outcome
The number of participants screened will be used as a measure of feasibility
Conditions Studied
Interventions
- OTHER Standard of Care
- BEHAVIORAL iRaPID
Study Locations (1)
Connecticut
- Yale Clinical and Community Research - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-07-26 |
| Est. Completion | 2023-02-28 |
| Phase | NA |
What the finished NCT04531670 record still lists
NCT04531670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Standard of Care is the first listed.
NCT04531670 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT04531670 about?
NCT04531670 is a clinical study titled "Testing of the Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs Program". This is a pilot study of an integrated rapid access HIV prevention program for People who inject drugs (PWID) called iRaPID. The program incorporates same-day access to Pre-exposure Prophylaxis (PrEP) and Opioid Agonist Therapy (OAT).
What is the current status of trial NCT04531670?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2021-07-26. Estimated completion is 2023-02-28.
What conditions does trial NCT04531670 study?
This clinical trial studies the following conditions: Opioid Use Disorder, HIV Prevention Program.
What interventions are being tested in trial NCT04531670?
The interventions under investigation include: Standard of Care (OTHER), iRaPID (BEHAVIORAL).
Who is sponsoring clinical trial NCT04531670?
This trial is sponsored by University of Connecticut, which has 107 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04531670 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04531670's enrollment target sits among peer trials
50 172nd of 257 higher than 80 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI